VIRBAC Lifts H1 Margin to 18.8% and Targets Top End of 2026 Guidance
The French animal health group posted 7.4% organic revenue growth, net income of €87.1 million and now aims for the upper end of its full-year range.
Virbac reported first-half 2026 revenue of €768 million, up 7.4% at constant exchange rates and scope and 4.0% at actual rates, with an adjusted EBIT margin before acquisition amortization of 18.8% against 18.3% a year earlier. Consolidated net income rose 5.9% to €87.1 million. On the strength of that first half, the animal health group now targets the upper end of its 2026 revenue growth range of 5.5% to 7.5% at constant rates and scope, with an adjusted recurring operating margin of around 17%.
